Lipo-Dox Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Doxorubicin HCl

Indications/Uses

Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients w/ low CD4 counts (<200 CD4 lymphocytes/mm³) & extensive mucocutaneous or visceral disease. 1st-line systemic chemotherapy or 2nd-line chemotherapy in AIDS-KS patients w/ disease progression or in patients intolerant to, prior combination systemic chemotherapy comprising of at least 2 of the following: Vinca alkaloid, bleomycin & standard doxorubicin (or other anthracyclines). In combination w/ bortezomib for progressive multiple myeloma in patients who have received at least 1 prior therapy & who have already undergone or unsuitable for bone marrow transplant.

Click to view Lipo-Dox detailed prescribing information

Dosage/Direction for Use

Breast/ovarian cancer 50 mg/m² IV once every 4 wk as long as the disease does not progress & patient continues to tolerate treatment. AIDS-KS patient 20 mg/m² IV every 2-3 wk for 2-3 mth. Multiple myeloma 30 mg/m²on day 4 of bortezomib 3-wk regimen as 1 hr infusion immediately after bortezomib infusion. Bortezomib regimen: 1.3 mg/m² on days 1, 4, 8 & 11 every 3 wk.

Click to view Lipo-Dox detailed prescribing information

Overdosage

View Lipo-Dox overdosage for action to be taken in the event of an overdose.

Contraindications

History of hypersensitivity. Not to be used in patients w/ AIDS-KS who are on local therapy or systemic α-interferon. Lactation.

Click to view Lipo-Dox detailed prescribing information

Special Precautions

Discontinue use if infusion-associated ARs occur. Impaired cardiac function; CHF due to cardiomyopathy; patients who have received other anthracyclines; persistent severe myelosuppression; diabetic patients. Not recommended in AIDS-KS patients w/ splenectomy. May affect ability to drive & operate machines. Not recommended during pregnancy. Not recommended in childn <18 yr.

Click to view Lipo-Dox detailed prescribing information

Use In Pregnancy & Lactation

Click to view Lipo-Dox detailed prescribing information

Adverse Reactions

Palmar-plantar erythrodysesthesia, stomatitis/mucositis & nausea; infusion-associated reaction; myelosuppression associated w/ anaemia, thrombocytopaenia, leukopaenia.

Click to view Lipo-Dox detailed prescribing information

Drug Interactions

Potentiated toxicity of other anti-cancer therapies. Exacerbated cyclophosphamide-induced hemorrhagic cystitits & enhanced hepatotoxicity of 6-mercaptopurine. Induced bone marrow suppression w/ other cytotoxic agents.

Click to view Lipo-Dox detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Lipo-Dox detailed prescribing information

Storage

View Lipo-Dox storage conditions for details to ensure optimal shelf-life.

Description

View Lipo-Dox description for details of the chemical structure and excipients (inactive components).

Action

View Lipo-Dox mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01DB01 - doxorubicin ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.

Regulatory Classification

Presentation/Packing

Form

Lipo-Dox infusion conc 2 mg/mL

Packing/Price

10 mL x 1's

Lipo-Dox

doxorubicin

Manufacturer:

TTY Biopharm

Distributor:

Pharm-D